All In Biotech

Drug Trial Radar · NCT07217119

Sub-study of Belantamab Mafodotin (GSK2857916) in Combination With Feladilimab (GSK3359609) in Participants With RRMM

A Phase I/II, Randomized, Open-label Platform Study Utilizing a Master Protocol to Study Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Anti-Cancer Treatments in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)-DREAMM5 - Sub-study 2 - Belantamab Mafodotin and Feladilimab (GSK3359609) in Combination

Last checked: Nov 19, 2026Latest source record: Jun 25, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

25

Actual

Start

Nov 26, 2019

Primary completion

Apr 17, 2025

Study completion Mar 11, 2027

Sponsor

Lead sponsor
GlaxoSmithKlineGSK (GSK)
Sponsor type
Industry
First posted
Oct 15, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary purpose is to determine the safety and tolerability of belantamab mafodotin in combination with feladilimab (GSK3359609), and to establish the recommended Phase 2 dose (RP2D) for the combination treatment to explore in the cohort expansion (CE) phase in participants with RRMM. This study is a sub study of the Master protocol (NCT04126200).

Conditions

  • Multiple Myeloma

Interventions

  • Belantamab mafodotinDrug

    Belantamab mafodotin will be administered.

  • FeladilimabDrug

    Feladilimab will be administered.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Expansion (DE) Phase: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Up to 28 days
  2. DE Phase: Number of Participants With Adverse Events (AEs)Time frame: Up to approximately 281 weeks
  3. DE Phase: Number of Participants With Worst-Case Hematology Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to approximately 281 weeks.
  4. DE Phase: Number of Participants With Worst-Case Chemistry Results by Maximum Grade Increase Post - Baseline Relative to BaselineTime frame: Baseline (Day 1) and up to approximately 281 weeks.
  5. Cohort Expansion (CE) Phase: Overall Response Rate (ORR)Time frame: Up to approximately 281 weeks.

Locations

11 sites in 8 countries. Site status is shown where the registry gives one.

  • GSK Investigational Site

    Atlanta, Georgia

  • GSK Investigational Site

    Madison, Wisconsin

  • GSK Investigational Site

    Fitzroy, Victoria, Australia

  • GSK Investigational Site

    Melbourne, Victoria, Australia

  • GSK Investigational Site

    Vancouver, British Columbia, Canada

  • GSK Investigational Site

    Toronto, Ontario, Canada

  • GSK Investigational Site

    Villejuif, France

  • GSK Investigational Site

    Hamburg, Germany

  • GSK Investigational Site

    Utrecht, Netherlands

  • GSK Investigational Site

    Pamplona Navarra, Spain

  • GSK Investigational Site

    Stockholm, Sweden

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.